News
RANI
0.7592
+1.36%
0.0102
H.C. Wainwright Sticks to Their Buy Rating for Rani Therapeutics Holdings (RANI)
TipRanks · 5d ago
Weekly Report: what happened at RANI last week (0914-0918)?
Weekly Report · 6d ago
Weekly Report: what happened at RANI last week (0907-0911)?
Weekly Report · 09/14 10:31
Weekly Report: what happened at RANI last week (0831-0904)?
Weekly Report · 09/07 10:24
Weekly Report: what happened at RANI last week (0824-0828)?
Weekly Report · 08/31 10:32
Rani Therapeutics Reports Q2 Update; RT-114 Expansion Data Expected By Year-End
NASDAQ · 08/27 11:27
Weekly Report: what happened at RANI last week (0817-0821)?
Weekly Report · 08/24 10:33
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Sanofi (OtherSNYNF)
TipRanks · 08/24 07:00
Rani Therapeutics Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 08/21 10:42
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Lifestance Health Group (LFST)
TipRanks · 08/21 10:40
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target
Benzinga · 08/21 10:31
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 08/18 12:45
Rani Therapeutics Initiated at Buy by Chardan Capital
Dow Jones · 08/18 12:04
Rani Therapeutics Price Target Announced at $6.00/Share by Chardan Capital
Dow Jones · 08/18 12:04
Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6
Benzinga · 08/18 11:53
Rani Therapeutics initiated with a Buy at Chardan
TipRanks · 08/18 11:10
Weekly Report: what happened at RANI last week (0810-0814)?
Weekly Report · 08/17 10:34
Rani Therapeutics GAAP EPS of -$0.04 beats by $0.01, revenue of $1.71M beats by $0.78M
Seeking Alpha · 08/13 20:36
Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate
Benzinga · 08/13 20:32
Press Release: Rani Therapeutics Reports Second -2-
Dow Jones · 08/13 20:05
More
Webull provides a variety of real-time RANI stock news. You can receive the latest news about Rani Therapeutics Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RANI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).